Urologic Oncology-seminars and Original Investigations最新文献

{"title":"Prognostic role of circRNAs and RNA methylation enzymes in bladder cancer: A systematic review and meta-analysis of Chinese studies.","authors":"Huanyu Ren, Lina Zou, Lan Jiang, Ping Zhang, Chunmei Li, Zheng Li, Huiru Niu, Xiaojing Zhang, Hao Liao, Lang Cheng, Feiyan Yang, Shanshan An, Xiuhong Ge, Fei Ren, Hongzhi Pan, Shengzhong Rong, Hongkun Ma","doi":"10.1016/j.urolonc.2025.06.005","DOIUrl":"https://doi.org/10.1016/j.urolonc.2025.06.005","url":null,"abstract":"<p><p>In recent years, some circRNAs and RNA methylation enzymes (including RNA methyltransferases and RNA demethylases) have been reported to be associated to the prognosis of bladder cancer, but the findings have been inconsistent. Therefore, the aims of this study is to comprehensively evaluate the prognostic value of circRNAs and RNA methylation enzymes as a whole in bladder cancer by Meta-analysis. A comprehensive literature search was performed in PubMed, Cochrane Library, EMbase, Web of Science, CNKI, WanFang, and VIP databases from the establishment of the database to March 2024. Data were extracted from the included literature and statistically analyzed using Stata 18.0 MP. (1) Overall survival (OS): high expression of circRNAs decreased OS of bladder cancer (HR = 1.74, 95% CI: 1.26-2.41, P = 0.001); and high fat mass and obesity-associated protein (FTO) expression led to poor OS in bladder cancer (HR = 2.38, 95% CI: 1.08-2.25, P = 0.032). (2) Disease-free survival (DFS): low circRNAs expression resulted in poor DFS (HR = 1.74, 95% CI: 1.38-2.18, P < 0.001); (3) Recurrence-free survival (RFS): high expression of circ-CCT3 and circ-RHOT1 decreased bladder cancer patients' RFS (HR = 2.26, 95% CI: 1.63-3.12, P < 0.001); and low expression of circ0004826 and circ0077837 also affected RFS (HR = 0.19, 95% CI: 0.08-0.43, P < 0.001). (4) 5-year survival: high expression of circRNAs decreased 5-year survival of bladder cancer patients (HR = 3.26, 95% CI: 1.90-5.57, P < 0.001). CircRNAs and FTO can be prognostic factors for bladder cancer.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144512557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential expression and hypermethylation of apoptotic genes in circulating nucleic acids are associated with clinical phenotypes of prostate cancer and benign prostatic hyperplasia in Nigerians.","authors":"Olayiwola Akanji Popoola, Titilola Aderonke Samuel, Comfort Folorunso, Idowu Taiwo, Olubunmi Magbagbeola, Oluyemi Akinloye","doi":"10.1016/j.urolonc.2025.06.001","DOIUrl":"https://doi.org/10.1016/j.urolonc.2025.06.001","url":null,"abstract":"<p><strong>Background: </strong>During carcinogenesis, cells have an increased ability to survive in the face of death-inducing mechanisms (apoptosis). Subversion of apoptosis is regarded as one of the primary factors helping the evolution of tumor cells. This study described the gene expression and DNA methylation of selected genes associated with apoptosis in prostate cancer (PCa) and benign prostatic hyperplasia (BPH).</p><p><strong>Methods: </strong>The study involved a total of 195 participants: 65 with prostate cancer, 65 with BPH, and 65 apparently healthy controls. Circulating DNA/RNA was extracted using Qiagen kits. RNA was reverse transcribed to cDNA while the isolated DNA was treated with bisulfite. The expression of each gene was determined by a qPCR reaction and DNA methylation was quantified using methylation-specific quantitative PCR.</p><p><strong>Results: </strong>We report differential expressions of BCL2, BOK, MCL1, and BAD genes in PCa group compared with controls(P < 0.05). The NOD1, CASP2, and CASP10 genes were differentially expressed(P < 0.05) in BPH and CASP7, CASP10, and MCL1 in PCa and BPH. A linear relationship exists between the expression of BCL2 and BOK and Gleason score in the PCa(P < 0.05). The expression of BOK gene shows a linear relationship with tumor burden(P < 0.05). There was an increase in methylation of BOK and ESR1 in PCa compared to BPH and controls(P < 0.05).</p><p><strong>Conclusion: </strong>We describe a differential expression of BCL2, BOK, BAD, and MCL1 and methylation of BOK and ESR1 genes in PCa in this study population for the first time. These differentially expressed and methylated genes can be explored for differential diagnosis, monitoring of treatment and new therapeutic targets.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144512556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcome of patients with a first relapse after intermediate- or high-risk Wilms tumor, treated according to SIOP WT 2001/UK-IMPORT study; A report from the SIOP renal tumor study group.","authors":"Alissa Groenendijk, Harm van Tinteren, Ronald R de Krijger, Gordan Vujanic, Reem Al-Saadi, Kathy Pritchard-Jones, Gema L Ramírez-Villar, Patrick Melchior, Jan Godzinski, Jens-Peter Schenk, Norbert Graf, Heidi Segers, Hélène Sudour-Bonnange, Arnauld C Verschuur, Jarno Drost, Daniela Perotti, Sarah Al-Jilaihawi, Jesper Brok, Marry M van den Heuvel-Eibrink, Filippo Spreafico, Annelies M C Mavinkurve-Groothuis","doi":"10.1016/j.urolonc.2025.05.018","DOIUrl":"10.1016/j.urolonc.2025.05.018","url":null,"abstract":"<p><strong>Background: </strong>Patients with a Wilms tumor (WT) who relapse following initial therapy with more than only vincristine and actinomycin-D are considered high-risk (group BB) or very high-risk (group CC) relapse by the International Society of Pediatric Oncology - Renal Tumor Study Group (SIOP-RTSG). We aimed to retrospectively analyze the characteristics and outcome of BB and CC patients.</p><p><strong>Methods: </strong>We included all patients with first relapsed WT that would currently be considered BB (n = 148) and CC (n = 72) relapse and registered in the SIOP 2001/UK-IMPORT study. We collected information on relapse treatment and calculated 5-year event-free (EFS) and overall survival (OS) rates per relapse risk group and treatment. Multivariable Cox regression analysis was performed to identify patient and tumor characteristics that were significantly associated with survival.</p><p><strong>Findings: </strong>The 5-year estimated EFS and OS rates of BB patients were 62·7% (95% CI: 54·9-71·6%) and 67·6% (95% CI: 59·8-76·4%), respectively. Five-year survival rates for the subset of BB patients treated with VAD and RT (n = 42/94) were 58·7% (95% CI: 45·0-76·6%) for EFS and 66·5% (95% CI: 53·1-83·2%) for OS. Five-year estimated EFS and rates for CC patients were 17·4% (95% CI: 10·4-29·0%) and 18·6% (95% CI: 11·3-30·5%), respectively. In multivariable Cox regression analysis, patients seemed to benefit from high dose chemotherapy and autologous stem cell rescue (HDCT) and surgery at first relapse.</p><p><strong>Interpretation: </strong>Second-line treatment was able to rescue two-thirds of BB relapse patients. In contrast, survival rates in CC patients at first relapse remain poor with conventional drugs, even with camptothecin-containing regimens. A subset of BB and CC patients may benefit from HDCT and surgery at relapse. However, to validate these findings, they must be reevaluated in future trials to eliminate bias from the analyses that is inherent to retrospective studies.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144369229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Renin-angiotensin system inhibitors and survival in patients with renal cell carcinoma: Evidence from a meta-analysis.","authors":"Hongyan Xi, Mingrui Zhao, Jinhai Shen","doi":"10.1016/j.urolonc.2025.05.015","DOIUrl":"10.1016/j.urolonc.2025.05.015","url":null,"abstract":"<p><strong>Background: </strong>The therapeutic potential of renin-angiotensin system inhibitors (RASi) in renal cell carcinoma (RCC) remains controversial. This meta-analysis synthesizes existing evidence to elucidate the association between RASi use and survival outcomes in RCC patients.</p><p><strong>Methods: </strong>We conducted a systematic search of PubMed, Scopus, and Embase up to November 12, 2024, to identify studies that compared survival outcomes between users and non-users of RASi. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for overall survival (OS) and progression-free survival (PFS) were calculated using random-effects models. Subgroup analyses stratified by disease stage, treatment modality, and the type of RASi were performed.</p><p><strong>Results: </strong>A total of 1,263 records were initially screened. Twelve retrospective studies, encompassing 22 cohorts and a combined total of 22,630 patients, were included in the final analysis. The pooled analysis revealed that RASi use was significantly associated with improved OS (HR, 0.74; 95% CI, 0.62-0.88) and PFS (HR, 0.74; 95% CI, 0.62-0.89). Notably, in patients with metastatic disease, the use of RASi was linked to an even greater enhancement in OS (HR, 0.71; 0.58-0.87) and PFS (HR, 0.72; 95%CI, 0.60-0.87). Subgroup analyses stratified by treatment modality indicated concurrent use of RASi with targeted therapy (HR, 0.69; 95% CI, 0.55-0.88) and immunotherapy (HR 0.55; 95% CI, 0.35-0.88) was associated with significantly improved OS.</p><p><strong>Conclusion: </strong>This meta-analysis suggests RASi as a potential adjunctive therapy in RCC management, particularly in patients with metastatic disease, and those who receive targeted therapy or immunotherapy. These findings highlight the potential therapeutic benefit of RASi in the management of RCC and warrant further investigation to establish its role in clinical practice guidelines.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncologic and renal function outcomes of segmental ureterectomy vs. radical nephroureterectomy in upper tract urothelial carcinoma: A systematic review and meta-analysis.","authors":"Alejandro Calvillo-Ramirez, Lauren Chew, Laura Davis, Ana Paulina Casas-Huesca, Luis A Esparza-Miranda, Valeria Michelle Perez Alvarado, Jesse Sanchez Cardenas, Juan Carlos Angulo-Lozano, Hannia M Macias-Cruz, Luis Robles-Aquije, Gilberto Perez Rodriguez Garcia, Randy Vince","doi":"10.1016/j.urolonc.2025.05.011","DOIUrl":"https://doi.org/10.1016/j.urolonc.2025.05.011","url":null,"abstract":"<p><p>Radical nephroureterectomy (RNU) remains the standard of care for patients with upper tract urothelial carcinoma (UTUC). Segmental ureterectomy (SU) has gained traction, given its benefit of preserving renal function without compromising oncologic control, particularly in low-risk disease. However, concerns persist regarding its oncological safety. We aimed to evaluate the oncologic and renal function outcomes in patients who underwent SU and RNU for UTUC. In August 2024, we systematically searched PubMed, Embase, Medline, and Cochrane databases to identify studies comparing oncologic outcomes and renal function preservation in patients who underwent SU and RNU for UTUC. Primary outcomes were cancer-specific survival (CSS), estimated glomerular filtration rate (eGFR) changes, and postoperative eGFR. Secondary outcomes included overall survival (OS), recurrence-free survival (RFS), and metastasis-free survival (MFS). Twenty-nine studies totaling 33,241 patients were included. No significant difference in 5-year CSS was observed between SU and RNU (HR 1.04, [95% confidence interval 0.93. 1.15], P = .49). A statistically significant higher 1-year postoperative eGFR (MD 17, [7.33, 26.67], P = .0006) and less pronounced eGFR change (MD 0.70, [0.24, 1.16], P = .003) were observed in the SU group. Additionally, the 5-year OS, RFS, and MFS were comparable between the groups. SU yielded comparable oncological outcomes to RNU concerning 5-year CSS, OS, RFS, and MFS while providing a higher postoperative eGFR and lower eGFR change at 1-year follow-up. SU might represent a viable treatment modality for UTUC in low-risk and carefully selected high-risk patients, although high-quality prospective trials implementing standardized outcome reporting are needed to draw definitive conclusions.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical management of tumors of the renal pelvis and parenchyma: focus on robotic approaches.","authors":"Craig G Rogers","doi":"10.1016/j.urolonc.2025.05.019","DOIUrl":"https://doi.org/10.1016/j.urolonc.2025.05.019","url":null,"abstract":"","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144276020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination regimen of intravesical docetaxel, gemcitabine, and cisplatin in patients with BCG-unresponsive bladder cancer: clinical outcomes and genomic correlations.","authors":"Benjamin I Joffe, John R Christin, Clémentine Le Coz, Prakash Gorroochurn, Jamie S Pak, Caroline Laplaca, Helena Vila Reyes, G Joel DeCastro, Christopher B Anderson, Cory Abate-Shen, Michael M Shen, James M McKiernan, Andrew T Lenis","doi":"10.1016/j.urolonc.2025.05.012","DOIUrl":"https://doi.org/10.1016/j.urolonc.2025.05.012","url":null,"abstract":"<p><strong>Purpose: </strong>Approximately 40% of non-muscle invasive bladder cancer patients who are treated with Bacillus Calmette-Guerin will experience treatment failure and recurrence. Many patients either refuse or are medically unfit for radical cystectomy. We aim to determine the efficacy and long-term durability of the novel triplet intravesical regimen of docetaxel, gemcitabine, and cisplatin as treatment for these patients.</p><p><strong>Materials and methods: </strong>This is a retrospective analysis of 16 patients recruited via volunteer sample at a tertiary care referral center in 2018-2023. Patients underwent a 6-week intravesical induction of weekly docetaxel, weekly gemcitabine, and biweekly cisplatin. In patients with treatment response, a maintenance regimen of monthly docetaxel and gemcitabine was initiated. Complete response was defined as negative cystoscopy with biopsy. Primary outcomes of interest were biopsy-proven recurrence, metastasis, and/or proceeding to cystectomy. Survival analysis was performed via Kaplan-Meier analysis.</p><p><strong>Results: </strong>Full induction was completed in all patients. At first follow-up, 12 patients (75%) had complete response and went on to maintenance therapy. Over follow-up, 7 patients (58%) recurred. By end of study period, 4/16 patients (25%) progressed, and 6/16 patients (37%) underwent cystectomy.</p><p><strong>Conclusions: </strong>In this highly-pretreated cohort of Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer patients, treatment with intravesical docetaxel, gemcitabine, and cisplatin shows a 75% complete response rate at 3-month follow up and a durable rate of 19%. These results are similar to various other options in this high-risk population.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A population-level analysis on the association of cannabis use and urologic cancers.","authors":"Ryan J Davis, Jacob Hershenhouse, Tyler J Gallagher, Navin Sabharwal, Michael A Daneshvar","doi":"10.1016/j.urolonc.2025.05.010","DOIUrl":"https://doi.org/10.1016/j.urolonc.2025.05.010","url":null,"abstract":"<p><strong>Objectives: </strong>While cannabis is the most commonly used illicit substance, studies surrounding its association with urologic cancers are few and limited by small samples, uncontrolled confounders, or infrequent patient cannabis use. We aimed to investigate the association between cannabis use and risk of genitourinary malignancies, using a large claims database.</p><p><strong>Methods: </strong>We retrospectively assessed United States adults between 2004 and 2024 in the TriNetX database. Those with prior genitourinary malignancies were excluded, and 2 cohorts were created based on having diagnoses of cannabis abuse/dependence or not. Cohorts were propensity score matched on demographic characteristics, tobacco use, nicotine dependence, substance-related disorders, and pertinent risk factors for each urologic malignancy, resulting in equal-sized cohorts. Final sample sizes varied following matching prior to analysis for each malignancy. Utilizing risk ratios, we assessed risk of developing bladder, kidney, prostate, upper tract, testis, and penile cancer any time after cannabis diagnosis.</p><p><strong>Results: </strong>Following exclusion, 74,642 patients with and 4,709,585 without cannabis dependence or abuse were identified. After matching, cannabis abuse or dependence was significantly associated with increased risk of bladder (0.14% vs. 0.03%, RR = 4.21, 95% CI = [2.70, 6.57]), kidney (0.17% vs. 0.05%, RR = 3.70, 95% CI = [2.52, 5.43]), and prostate cancer (0.61% vs. 0.22%, RR = 2.80, 95% CI = [2.19, 3.58]). No significant association was found for upper tract, testis, or penile cancer.</p><p><strong>Conclusions: </strong>We add to literature supporting the relationship between cannabis and bladder, kidney, and prostate cancer. As testis and penile cancer are relatively rare, however, we cannot exclude an association with these cancers. Future studies should investigate a dose-dependent relationship.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-based differences in genetic alterations and immune checkpoint inhibitor response in urothelial bladder cancer.","authors":"Jean-Pierre Trey Kanumuambidi, Reynier Rodriguez Rosales, Arjun Venkatesh, Thomas Metzner, Nicole Murray, Mohammed Al-Toubat, Yudai Ishiyama, Hunter Sceats, Mark Bandyk, K C Balaji","doi":"10.1016/j.urolonc.2025.05.013","DOIUrl":"https://doi.org/10.1016/j.urolonc.2025.05.013","url":null,"abstract":"<p><strong>Introduction: </strong>Bladder cancer exhibits significant sex-based disparities, with men showing higher incidence rates and women experiencing more aggressive disease and poorer survival outcomes. This study investigates sex-specific somatic genetic alterations (GAs) in urothelial bladder cancer and their effects on survival, immune cell infiltration, and immune checkpoint inhibitor (ICI) responses.</p><p><strong>Methods: </strong>We analyzed 3,157 patients with urothelial bladder cancer using next-generation sequencing data from the American Association for Cancer Research (AACR) Project GENIE. Kaplan-Meier analysis assessed overall survival, while TIMER2.0 and ROC Plotter evaluated immune cell infiltration and ICI responses. Synthetic lethal interactions were identified through the SLOAD database, and co-occurrence patterns were examined (significance at P < 0.05).</p><p><strong>Results: </strong>Among the 3,157 patients (median age: 70), 76% were male. Somatic gene alterations were identified in 35% of cases, more frequently in men (38% vs. 29%, P < 0.001). Men had more alterations in RB1, CDKN1A, and ERCC2 (all P < 0.001), while AR gene alterations were more common in women. Patients with CDKN1A, RB1, or ERCC2 alterations had significantly worse 5-year survival (18-27 vs. 35.4 months; P = 0.0219), with RB1 alterations linked to the lowest 10-year survival rates (21.3% vs. 28.3%, P = 0.0219). Immune profiling revealed increased CD8⁺ T cell and NK cell infiltration in RB1-altered tumors, while AR alterations correlated with decreased monocyte infiltration.</p><p><strong>Conclusion: </strong>Somatic GAs contribute to sex-based survival disparities in bladder cancer. RB1 and AR alterations emerge as critical drivers of poor outcomes and potential therapeutic targets, underscoring the need for sex-tailored treatment strategies.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A polygenic risk score is associated with risk of bladder cancer and earlier age of diagnosis, independent of lifestyle factors.","authors":"David J Nusbaum, Zhuqing Shi, Annabelle Ashworth, Huy Tran, Jun Wei, Aaron S Dahmen, Piyush K Agarwal, Craig V Labbate, Brian T Helfand, Jianfeng Xu","doi":"10.1016/j.urolonc.2025.05.009","DOIUrl":"https://doi.org/10.1016/j.urolonc.2025.05.009","url":null,"abstract":"<p><strong>Background: </strong>Genetic risk factors are not currently incorporated into the clinical evaluation of patients at risk for bladder cancer (BCa). The objective of this study is to assess the independent and joint effects of genetic and lifestyle factors on the risk of developing BCa and age at diagnosis.</p><p><strong>Methods: </strong>This is a population-based cohort study of the UK Biobank, consisting of 3,373 BCa cases and 481,275 controls. A polygenic risk score (PGS) was calculated and the effect of lifestyle and genetic factors on BCa risk was estimated using hazard ratio (HR).</p><p><strong>Results: </strong>The PGS was a significant and independent predictor of the risk of BCa diagnosis. Compared to never-smokers with BMI <30 and a PGS in the lowest decile, current smoking was associated with a HR of 4.47 (95% CI 3.35-5.98) and a PGS in the highest decile was associated with a HR of 4.57 (95% CI 3.44-6.09). Risk was highest for current smokers with BMI ≥30 and a PGS in the highest decile (HR 8.14, 95% CI 4.95-13.36). Most study subjects (∼95%) were of European ancestry.</p><p><strong>Conclusion: </strong>The PGS was an independent and significant predictor of the risk of BCa and earlier age at diagnosis. The effect size of PGS in the highest decile was similar to that of smoking. Joint effects were observed with smoking status and BMI. These data provide support for incorporating measures of genetic risk factors in efforts to improve early detection of BCa.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}